August 27, 2019
This morning FIGUR8, a new digital platform designed to measure and track body movements as a biomarker, launched with a boost of $7.5 million seed funding. The funding was led by P5 Health Ventures with participation from E14 Fund.
Co-created by researchers at MIT Media Lab and Massachusetts General Hospital Sports Science Lab, the technology was developed with the goal of creating a baseline...
March 28, 2019
This morning Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $4.75 million in extended Series A financing. This new capital was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
This latest funding announcement will build on the $10 million the company raised in November of 2017, bringing the total Series A capital to...
MIT's CSAIL institute is located in the Stata Center. Credit: Google Maps
August 20, 2018
ReMix, a new technology in the works at MIT's Computer Science and Artificial Intelligence Laboratory, seeks to make progress toward a new paradigm of treatment – one that's less reliant on endoscopy and surgery, but instead relies on sensors and what scientists call an "in-body GPS" to help make diagnoses and guide drug administration.
The goal, researchers said, is a new approach to patient...
August 14, 2018
Profusa, a company that is developing connected tissue-implanted biosensors, has raised just over $45 million in Series C funding. Participants in the round included new investors VMS Investment Group, Tasly Pharmaceutical Group, and Maxim Integrated, as well as returning backers 3E Bioventures Capital and Atinum Investment.
The company will be using the new financing to bring its CE Marked...
October 31, 2017
Silicon Valley-based VitalConnect, a producer of wireless wearable monitoring devices, announced the closure of a $38 million Series C funding round. The funding round was led by MVM and Baxter Ventures, with participation from Mercy.
VitalConnect is best known for its FDA-cleared, disposable peel-and-stick health sensor, the VitalPatch. Combined with a software platform, the wearable...
February 15, 2017
GluSense, an Israeli medical device company, announced an undisclosed investment from the JDRF T1D Fund, a recently launched VC philanthropy fund dedicated to funding early stage programs for Type 1 diabetes. GluSense is being incubated in the Rainbow Medical innovation house, a private investment company that seeds and grows medical device companies.
The company’s first product in development is...
January 12, 2017
When monitoring heart rate, skin temperatures, activity and other physiological data, biometric-sensing wearables are also tracking important indications of abnormality associated with infection, inflammation or even insulin. By extension, wearables may know the user is getting sick before they even do, according to new research from Stanford University published today in PLOS Biology.
November 7, 2016
Pharmaceutical company Takeda is looking to up its digital strategy game, pairing with a few companies to advance clinical trials, analyze data and develop biosensor and wearable technology.
Takeda has adopted the platform of Koneska Health, an early stage technology company that works with data gathered through mobile, wearable and other digital technologies to measure health indicators, to...
December 12, 2013
A team from the University of California Santa Barbara has developed a technique for continuous monitoring of the saturation of drugs in the bloodstream. While technology has existed to monitor saturation at intervals, and to continuously monitor certain specific substances like glucose, this is the first potentially modular, continuous sensor.
This could allow doctors to more quickly and...
March 11, 2009
American Public Media's Marketplace radio program had a quick piece on wireless medicine recently that included interviews with a number of doctors. Leslie Saxon, head of cardiovascular medicine at the University of Southern California, said during the program that she would guess there nearly a "half million patients with networked-implanted devices" like wirelessly-connected heart monitors.